The study included 6,871 patients and showed that users of GLP-1 medications had a five-year mortality of 15.5%, compared with 37.1% among those who did not use GLP-1
However, some people may tolerate Mounjaro better, as the side effect profile can vary from person to person
Kaufman believes that by reducing systemic inflammation, GLP-1 agonists are targeting one of the root causes of these diseases and helping fight reactivated pathogens such as EBV
All research involving this compound is limited to experimental models
Tirzepatide's dual mechanism may confer additional metabolic benefits, though cardiovascular outcome trials are still ongoing to provide definitive evidence
Challenges include infrastructural limitations, regulatory complexities, and the need for technological upgrades in local manufacturing facilities